Cargando…
The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042076/ https://www.ncbi.nlm.nih.gov/pubmed/35498630 http://dx.doi.org/10.2147/IDR.S356460 |
_version_ | 1784694601662070784 |
---|---|
author | Li, Jianwu Jiang, Na Zeng, Qing-Lei Zhang, Yue He, Xinyuan Chu, Yao Jin, Wenni Liu, Yi Shi, Wan Yang, Miao He, Weihan Han, Qing Ma, Le Xu, You Guo, Yaling Zhang, Lei Ji, Fanpu |
author_facet | Li, Jianwu Jiang, Na Zeng, Qing-Lei Zhang, Yue He, Xinyuan Chu, Yao Jin, Wenni Liu, Yi Shi, Wan Yang, Miao He, Weihan Han, Qing Ma, Le Xu, You Guo, Yaling Zhang, Lei Ji, Fanpu |
author_sort | Li, Jianwu |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features of these vaccines infected with SARS-CoV-2 can be identified. METHODS: We retrospectively collected and analyzed epidemiological and clinical characteristics data of the imported COVID-19 cases who received Chinese inactivated vaccines abroad. Data were extracted from electronic medical records from a designated hospital in the Shaanxi Province of China between March 22 and May 17, 2021. RESULTS: Totally, 46 confirmed SARS-CoV-2 infection patients were enrolled. The mean age was 40.5 years (range 20–61), 41 (89.1%) are male. Eighteen (39.1%) patients were from Pakistan. Fourteen (30.4%) patients had at least one comorbidity. Forty (87.0%) and 6 cases were fully vaccinated and partly vaccinated. The time interval between vaccination and infection was 88 days (IQR, 33–123), 31 (67.4%) and 15 (32.6%) were asymptomatic and symptomatic cases, respectively. Fever (3/46, 6.5%) was the most common symptom; however, none had a body temperature higher than 38.0°C, and no severe case was observed. Notably, the rate of SARS-CoV-2 shedding discontinuation at 7 days after hospitalization in asymptomatic cases was higher than symptomatic one (93.5% vs 40%, P < 0.0001). CONCLUSION: Individuals who received Chinese inactivated vaccines abroad remain to have the probability of being infected with SARS-CoV-2, but all the vaccines infected with SARS-CoV-2 were asymptomatic or had mild symptoms with favorable clinical outcomes. |
format | Online Article Text |
id | pubmed-9042076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90420762022-04-27 The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection Li, Jianwu Jiang, Na Zeng, Qing-Lei Zhang, Yue He, Xinyuan Chu, Yao Jin, Wenni Liu, Yi Shi, Wan Yang, Miao He, Weihan Han, Qing Ma, Le Xu, You Guo, Yaling Zhang, Lei Ji, Fanpu Infect Drug Resist Original Research BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features of these vaccines infected with SARS-CoV-2 can be identified. METHODS: We retrospectively collected and analyzed epidemiological and clinical characteristics data of the imported COVID-19 cases who received Chinese inactivated vaccines abroad. Data were extracted from electronic medical records from a designated hospital in the Shaanxi Province of China between March 22 and May 17, 2021. RESULTS: Totally, 46 confirmed SARS-CoV-2 infection patients were enrolled. The mean age was 40.5 years (range 20–61), 41 (89.1%) are male. Eighteen (39.1%) patients were from Pakistan. Fourteen (30.4%) patients had at least one comorbidity. Forty (87.0%) and 6 cases were fully vaccinated and partly vaccinated. The time interval between vaccination and infection was 88 days (IQR, 33–123), 31 (67.4%) and 15 (32.6%) were asymptomatic and symptomatic cases, respectively. Fever (3/46, 6.5%) was the most common symptom; however, none had a body temperature higher than 38.0°C, and no severe case was observed. Notably, the rate of SARS-CoV-2 shedding discontinuation at 7 days after hospitalization in asymptomatic cases was higher than symptomatic one (93.5% vs 40%, P < 0.0001). CONCLUSION: Individuals who received Chinese inactivated vaccines abroad remain to have the probability of being infected with SARS-CoV-2, but all the vaccines infected with SARS-CoV-2 were asymptomatic or had mild symptoms with favorable clinical outcomes. Dove 2022-04-22 /pmc/articles/PMC9042076/ /pubmed/35498630 http://dx.doi.org/10.2147/IDR.S356460 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Jianwu Jiang, Na Zeng, Qing-Lei Zhang, Yue He, Xinyuan Chu, Yao Jin, Wenni Liu, Yi Shi, Wan Yang, Miao He, Weihan Han, Qing Ma, Le Xu, You Guo, Yaling Zhang, Lei Ji, Fanpu The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title | The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title_full | The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title_fullStr | The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title_full_unstemmed | The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title_short | The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection |
title_sort | epidemiological, clinical features and outcomes of imported chinese covid-19 patients following inactivated vaccines injection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042076/ https://www.ncbi.nlm.nih.gov/pubmed/35498630 http://dx.doi.org/10.2147/IDR.S356460 |
work_keys_str_mv | AT lijianwu theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jiangna theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zengqinglei theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zhangyue theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT hexinyuan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT chuyao theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jinwenni theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT liuyi theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT shiwan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT yangmiao theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT heweihan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT hanqing theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT male theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT xuyou theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT guoyaling theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zhanglei theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jifanpu theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT lijianwu epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jiangna epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zengqinglei epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zhangyue epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT hexinyuan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT chuyao epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jinwenni epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT liuyi epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT shiwan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT yangmiao epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT heweihan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT hanqing epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT male epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT xuyou epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT guoyaling epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT zhanglei epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection AT jifanpu epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection |